News
AMPH
29.38
+3.12%
0.89
Amphastar price target raised to $23 from $20 at BofA
TipRanks · 2d ago
How Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Strong Third Quarter Earnings
Simply Wall St · 2d ago
Analysts Conflicted on These Healthcare Names: Elicio Therapeutics (ELTX), Amphastar Pharmaceuticals (AMPH) and Sarepta Therapeutics (SRPT)
TipRanks · 2d ago
Amphastar (AMPH) Q3 2026 Earnings Call Transcript
The Motley Fool · 3d ago
Amphastar Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 3d ago
Amphastar Pharmaceuticals Price Target Raised to $25.00/Share From $20.00 by Wells Fargo
Dow Jones · 3d ago
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $25
Benzinga · 3d ago
Amphastar Pharmaceuticals (AMPH) On Q3 Results Faces An Overvalued Narrative
Simply Wall St · 3d ago
Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
NASDAQ · 4d ago
*Amphastar Pharmaceuticals 3Q Rev $207.6M >AMPH
Dow Jones · 4d ago
Press Release: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
Dow Jones · 4d ago
Press Release: Amphastar Pharmaceuticals Reports -2-
Dow Jones · 4d ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
PR Newswire · 4d ago
Amphastar Pharmaceuticals (NASDAQ:AMPH) reports bullish Q3 2026, stock soars
Barchart · 4d ago
Here are the major earnings after the close Thursday
Seeking Alpha · 4d ago
Based on the search results, Amphastar Pharmaceuticals (AMPH) is scheduled to report Q3 2026 earnings tomorrow (November 5, 2026). The key themes emerging are:
Barchart · 5d ago
Weekly Report: what happened at AMPH last week (1026-1030)?
Weekly Report · 11/02 09:53
3 profitable stocks with warning signs
Barchart · 10/30 04:20
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 10/29 20:10
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
PR Newswire · 10/29 10:00
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.